Shows
Research To Practice | Oncology VideosRelapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 ReviewFeaturing an interview with Dr Sagar Lonial, including the following topics: KLN-1010: A novel, in vivo gene therapy generating anti-BCMA chimeric antigen receptor T cells (0:00) Phase III DREAMM-7 and DREAMM-8 studies of belantamab mafodotin-based combination therapy for patients with relapsed/refractory (R/R) multiple myeloma (MM) (5:37) Effectiveness of ciltacabtagene autoleucel for patients with R/R MM (11:04) Low-dose tocilizumab for mitigation of the cytokine release syndrome associated with bispecific antibodies (16:04) Talquetamab with teclistamab for patients with R/R MM in Phase Ib of the RedirecTT-1 trial (19:24) CME information and select publications
2026-02-0323 min
Hematologic Oncology UpdateRelapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 ReviewDr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.
2026-02-0323 min
Oncology Today with Dr Neil LoveRelapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 ReviewDr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.
2026-02-0323 min
Research To Practice | Oncology VideosRelapsed/Refractory Multiple Myeloma — ASH 2025 ReviewFeaturing perspectives from Dr Sagar Lonial and Dr María-Victoria Mateos, including the following topics: Introduction (0:00) Best of ASH Multiple Myeloma (1:56) Case: A man in his late 50s with t(11;14) IgA kappa myeloma discovered during workup for new Stage IV kidney disease who has a chest wall plasmacytoma receives daratumumab with CyBorD and radiation therapy to the plasmacytoma with minimal response — Jeremy Lorber, MD (8:35) Antibody-Drug Conjugates and Other Emerging Novel Therapies for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lonial (16:58) Case: A man in his mid 80s with severe obesity and coronary artery disease, chronic heart failure and sl...
2026-01-171h 01
Multiple Myeloma HubImproving access to CAR T-cell therapy for eligible patients with MMDuring the Multiple Myeloma Hub Steering Committee Meeting in November 2025, key opinion leaders met to discuss improving access to chimeric antigen receptor (CAR) T-cell therapy for eligible patients with multiple myeloma. The meeting opened with a presentation by Sagar Lonial and featured a discussion including Morie Gertz, Elena Zamagni, Meral Beksaç, and Sonia Zweegmann. During his presentation, Lonial provided an overview of approved and investigational CAR T-cell therapies for multiple myeloma, the CAR T-cell therapy treatment process, and multi-step treatment pathway. He explored barriers to treatment with CAR T-cell therapy, racial disparities in access to C...
2026-01-0629 min
Society of Hematologic Oncology Insider newsSagar Lonial, MD, on what to expect at SOHO Breakthroughs in Blood CancersSagar Lonial, MD, and Saad Usmani, MD, provide a sneak peek on what attendees can expect to learn at SOHO Breakthroughs in Blood Cancers (SBBC). Dr. Lonial will be the presenter of the myeloma session at the meeting. His talk is scheduled for 1:35 pm Central time on November 20, 2025.
SBBC is a new virtual meeting from SOHO and is chaired by Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center. SBBC takes place at 8 am—5 pm Central time on November 20, 2025. Register today at soho.click/SBBC. To view the entire program, visit the SBBC website.
...
2025-10-1701 min
Research To Practice | Oncology VideosRelapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by PatientsFeaturing perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics: Introduction (0:00) A Farmer with Myeloma; Is Myeloma the New Chronic Myeloid Leukemia? (2:06) Clinical Trials (12:34) Chimeric Antigen Receptor Therapy (16:11) Bispecific Antibodies (21:38) Antibody-Drug Conjugates; a Patient on Belantamab Mafodotin for 3 Years (30:45) Treatment Options for Relapsed Disease (40:46) Neuropathy (44:43) Alternative Therapies (48:36) 164 Questions (53:20) CME information and select publications
2025-08-2959 minHematologic Oncology UpdateRelapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by PatientsDr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. CME information and select publications here.
2025-08-2959 minOncology Today with Dr Neil LoveRelapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by PatientsDr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. CME information and select publications here.
2025-08-2959 min
CMEMastering the Sequence: CELMoDs Across Treatment Lines
Faculty: Sagar Lonial, MD, FACP
Faculty: Noopur Raje, MD
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential...
2025-08-2105 minCMEData Dive: Clinical Evidence Behind CELMoDs
Faculty: Sagar Lonial, MD, FACP
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents...
2025-08-2106 minCMEWhy CELMoDs Matter in Myeloma
Faculty: Sagar Lonial, MD, FACP
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents...
2025-08-2105 minCME/CECase Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Faculty: Joshua Richter, MD
Faculty: Sagar Lonial, MD, FACP
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential...
2025-08-2105 minCME/CEReal-World Ready: Practical Tips for Community Oncologists
Faculty: Joshua Richter, MD
Faculty: Sagar Lonial, MD, FACP
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential...
2025-08-2106 minCME/CEMastering the Sequence: CELMoDs Across Treatment Lines
Faculty: Sagar Lonial, MD, FACP
Faculty: Noopur Raje, MD
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential...
2025-08-2105 minCME/CEPrecision Targeting: Matching CELMoDs to the Right Patient With Myeloma
Faculty: Sagar Lonial, MD, FACP
Faculty: Noopur Raje, MD
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential...
2025-08-2105 minCME/CEData Dive: Clinical Evidence Behind CELMoDs
Faculty: Sagar Lonial, MD, FACP
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents...
2025-08-2106 minCME/CEWhy CELMoDs Matter in Myeloma
Faculty: Sagar Lonial, MD, FACP
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential role of these novel agents...
2025-08-2105 minCMEReal-World Ready: Practical Tips for Community Oncologists
Faculty: Joshua Richter, MD
Faculty: Sagar Lonial, MD, FACP
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential...
2025-08-2106 minCMECase Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Faculty: Joshua Richter, MD
Faculty: Sagar Lonial, MD, FACP
Despite recent therapeutic advances, most patients with multiple myeloma continue to face the challenge of an incurable disease and undergo cycles of remission and relapse, with the eventual development of resistance to existing therapies. This highlights the persistent need for more effective and durable treatment strategies. CELMoDs are a class of drugs that enhance T cell potency, promote combinational synergy with other antimyeloma agents, and rejuvenate exhausted T cells to improve antimyeloma effects even in T cell-exhausted settings. Dive into this series of activities to discover the potential...
2025-08-2105 minMultiple Myeloma HubWhat might be the future applications for BCMA-directed bispecific antibodies in MM and other PCD?The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What might be the future applications for B-cell maturation antigen (BCMA)-directed bispecific antibodies in multiple myeloma (MM) and other plasma cell dyscrasias?In this interview, Sagar Lonial discussed the expanding role of BCMA-directed bispecific antibody therapies beyond relapsed/refractory MM, including their potential applications in high-risk smoldering MM and light-chain (AL) amyloidosis. Lonial also evaluated emerging strategies for optimizing dosing schedules, enhancing the patient experience, and mitigating treatment resistance.This educational resource is independently su...
2025-08-1808 minHematologic Oncology UpdateMultiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple MyelomaFor this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia, to discuss the patient experience associated with the diagnosis and treatment of relapsed/refractory multiple myeloma. Educational and faculty information here.
2025-08-151h 02
Research To Practice | Oncology VideosMultiple Myeloma | Oncology Q&A for Patients: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple MyelomaFeaturing perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics: Introduction: Multiple Myeloma — 2005 to 2025 (0:00) Questions from the Beginning (7:53) Choosing Options (13:54) Clinical Trials (18:03) Neuropathy (23:55) Chimeric Antigen Receptor (CAR) T-Cell Therapy (28:40) Bispecific Antibodies (35:18) Antibody-Drug Conjugates (43:08) Interacting with the Oncology Team (51:47) Other Questions (57:30) Educational and presenter information
2025-08-151h 02Oncology Today with Dr Neil LoveMultiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple MyelomaFor this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia, to discuss the patient experience associated with the diagnosis and treatment of relapsed/refractory multiple myeloma. Educational and faculty information here.
2025-08-141h 02
PeerView Clinical Pharmacology CME/CNE/CPE VideoSagar Lonial, MD, FACP - 4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FVK865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed Disease In support of improving patient care, this activity has been planned...
2025-07-221h 44
PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - 4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FVK865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed Disease In support of improving patient care, this activity has been planned...
2025-07-221h 44
PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP - 4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FVK865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed Disease In support of improving patient care, this activity has been planned...
2025-07-221h 44
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - 4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FVK865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed Disease In support of improving patient care, this activity has been planned...
2025-07-221h 44
PeerView Oncology & Hematology CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP - 4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FVK865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed Disease In support of improving patient care, this activity has been planned...
2025-07-221h 44
PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - 4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed DiseaseThis content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/FVK865. CME/MOC/AAPA/IPCE credit will be available until June 30, 2026.4x4 in Multiple Myeloma: Maintaining Momentum for Delivering Innovative Care in Newly Diagnosed and Relapsed Disease In support of improving patient care, this activity has been planned...
2025-07-221h 44
Decera Clinical Education Oncology PodcastExperts Discuss CELMoDs in MyelomaIn this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including: Mechanistic differences between CELMoDs and IMiDsEmerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myelomaThe clinical implications of MRD negativity as a surrogate marker of long-term outcomes in clinical trials in multiple myelomaPresenters:Jesus Berdeja, MDDirector of Myeloma ResearchGreco-Hainsworth Centers for ResearchTennessee OncologyNashville, TennesseeAmrita Krishnan, MD, FACPDirector, Judy and Bernard B...
2025-07-1535 minSociety of Hematologic Oncology Insider newsThe journey of belantamab mafodotin in multiple myelomaHost Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center in New York City, and Sagar Lonial, MD, FACP, professor and chair of the Department of Hematology and Medical Oncology at Winship Cancer Institute at Emory University, explore the journey of the antibody-drug conjugate (ADC) belantamab mafodotin, the first B-cell maturation antigen (BCMA)-targeted ADC approved by the US Food and Drug Administration (FDA) for patients with relapsed or refractory myeloma.
Dr. Lonial noted the excitement around the approval given how few treatment options there were for this subgroup of patients.
2025-07-0709 minMultiple Myeloma HubWhat is the rationale for treating early RRRM with targeted therapies?The Multiple Myeloma Hub spoke to Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What is the rationale for treating early relapsed/refractory multiple myeloma (RRMM) with targeted therapies? In this interview, Lonial discusses how the treatment landscape for early RRMM has changed over time, impacting the effectiveness of standard of care therapies and leading to an increased interest in new targeted approaches, such as CAR T-cell therapies, bispecific antibodies, and antibody–drug conjugates. Lonial outlines the latest regulatory updates and available options for patients who are ineligible for or unable to...
2025-05-0204 min
Research To Practice | Oncology VideosMultiple Myeloma | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Multiple MyelomaFeaturing perspectives from Dr Sagar Lonial, Prof Philippe Moreau, Dr Robert Z Orlowski, Dr Noopur Raje and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics: Introduction (0:00) Management of Newly Diagnosed Multiple Myeloma (MM) — Dr Orlowski (1:26) Integration of Novel Therapies into the Management of Relapsed/Refractory MM — Dr Richardson (26:53) Chimeric Antigen Receptor T-Cell Therapy for MM — Dr Raje (48:48) Bispecific Antibodies for the Treatment of MM — Prof Moreau (1:12:52) Other Novel Agents and Strategies Under Investigation for MM — Dr Lonial (1:36:32) CME information and select publications
2024-12-211h 57Hematologic Oncology UpdateMultiple Myeloma — Part 6 of Our 6-Part ASH 2024 Friday Satellite Symposia SeriesProf Philippe Moreau of University Hospital – CHU de Nantes in France, Dr Robert Z Orlowski of The University of Texas MD Anderson Cancer Center in Houston, Dr Noopur Raje of Massachusetts General Hospital Cancer Center in Boston, Dr Paul G Richardson of Dana-Farber Cancer Institute in Boston, and Dr Sagar Lonial of Winship Cancer Institute of Emory University in Atlanta, Georgia, discuss current questions and controversies in the management of multiple myeloma.
2024-12-201h 57
Oncology Today with Dr Neil LoveMultiple Myeloma — Part 6 of Our 6-Part ASH 2024 Friday Satellite Symposia Series
Prof Philippe Moreau of University Hospital – CHU de Nantes in France, Dr Robert Z Orlowski of The University of Texas MD Anderson Cancer Center in Houston, Dr Noopur Raje of Massachusetts General Hospital Cancer Center in Boston, Dr Paul G Richardson of Dana-Farber Cancer Institute in Boston, and Dr Sagar Lonial of Winship Cancer Institute of Emory University in Atlanta, Georgia, discuss current questions and controversies in the management of multiple myeloma. Produced by Research To Practice.
CME information and select publications here.
2024-12-201h 57
Research To Practice | Oncology VideosMultiple Myeloma | Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology CareFeaturing perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Current Therapeutic Approaches for Multiple Myeloma — Dr Lonial (0:37) Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Raje (22:53) CME information and select publications
2024-11-2652 min
Research To Practice | Oncology VideosNon-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology CareFeaturing perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Updates in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma — Dr Kahl (1:10) Updates in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Dr S Smith (33:32) CME information and select publications
2024-11-2056 min
Research To Practice | Oncology VideosProstate Cancer | Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology CareFeaturing perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Role of Hormonal Therapy in Prostate Cancer Management — Dr M Smith (10:54) Other Available and Emerging Therapeutic Approaches — Dr Srinivas (37:03) CME information and select publications
2024-11-2057 min
Research To Practice | Oncology VideosLung Cancer | Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology CareFeaturing perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Nontargeted Therapy for Lung Cancer — Dr Goldberg (9:07) Targeted Therapy for Non-Small Cell Lung Cancer — Dr Sabari (51:19) CME information and select publications
2024-11-161h 05
Research To Practice | Oncology VideosHR-Positive Breast Cancer | Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology CareFeaturing perspectives from Dr Sarah B Goldberg, Dr Brad S Kahl, Dr Sagar Lonial, Dr Joyce O'Shaughnessy, Dr Noopur Raje, Dr Joshua K Sabari, Dr Matthew R Smith, Dr Sonali M Smith, Dr Sandy Srinivas and Dr Seth Wander, including the following topics: Introduction (0:00) Hormone Receptor-Positive Breast Cancer — Dr O'Shaughnessy (10:45) Management of Relapsed/Refractory HR-Positive Metastatic Breast Cancer — Dr Wander (40:47) CME information and select publications
2024-11-161h 03Multiple Myeloma HubSymposium | How to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myelomaDuring the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium entitled ‘Sequencing immune-based therapies in B-cell malignancies’. Here, the Multiple Myeloma Hub is pleased to share the session, which covered how to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory (R/R) multiple myeloma (MM), presented by Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. Hosted on Acast. See acast.com/privacy for more information.
2024-08-0926 min
CME in Minutes: Education in Oncology & HematologySagar Lonial, MD, FACP - Accelerating Targeted Degradation in Multiple Myeloma: The Role of CELMoDs in Overcoming IMiD Resistance in Earlier Lines of TherapyPlease visit answersincme.com/DMQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the role of CELMoDs in overcoming IMiD resistance in earlier lines of therapy for multiple myeloma. Upon completion of this activity, participants should be better able to: Explain the biologic rationale for investigating novel CELMoDs in earlier lines of therapy in patients with multiple myeloma (MM); Review the clinical significance of late-stage trials of emerging CELMoDs in the maintenance and earlier-relapse settings in patients with MM; and Outline the clinical considerations for integrating...
2024-07-0514 min
CME in Minutes: Education in Primary CareSagar Lonial, MD, FACP - Accelerating Targeted Degradation in Multiple Myeloma: The Role of CELMoDs in Overcoming IMiD Resistance in Earlier Lines of TherapyPlease visit answersincme.com/DMQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the role of CELMoDs in overcoming IMiD resistance in earlier lines of therapy for multiple myeloma. Upon completion of this activity, participants should be better able to: Explain the biologic rationale for investigating novel CELMoDs in earlier lines of therapy in patients with multiple myeloma (MM); Review the clinical significance of late-stage trials of emerging CELMoDs in the maintenance and earlier-relapse settings in patients with MM; and Outline the clinical considerations for integrating...
2024-07-0514 min
touchPODCASTThe rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trialstouchEXPERT OPINIONS for touchHAEMATOLOGY
Three internationally renowned multiple myeloma experts share insights into the unmet treatment needs for patients with relapsed/refractory multiple myeloma, the rationale for emerging protein degradation and immunomodulation-based therapies, and the latest data and ongoing clinical trials for these investigational agents.
The experts
Prof. Cristina Gasparetto - Duke Cancer Institute, Durham, NC, USA
Prof. Sagar Lonial - Emory University, Atlanta, GA, USA
Prof. Sundar Jagannath - Tisch Cancer Institute, New York, NY, USA
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical e...
2024-02-0934 mintouchPODCASTThe rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trialstouchEXPERT OPINIONS for touchONCOLOGY
Three internationally renowned multiple myeloma experts share insights into the unmet treatment needs for patients with relapsed/refractory multiple myeloma, the rationale for emerging protein degradation and immunomodulation-based therapies, and the latest data and ongoing clinical trials for these investigational agents.
The experts
Prof. Cristina Gasparetto - Duke Cancer Institute, Durham, NC, USA
Prof. Sagar Lonial - Emory University, Atlanta, GA, USA
Prof. Sundar Jagannath - Tisch Cancer Institute, New York, NY, USA
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical e...
2024-02-0934 min
Research To Practice | Oncology VideosMultiple Myeloma | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Multiple MyelomaFeaturing perspectives from Dr Amrita Krishnan, Dr Sagar Lonial, Dr Robert Z Orlowski, Dr Noopur Raje and Dr Paul G Richardson, including the following topics: • Introduction (0:00) • Management of Newly Diagnosed Multiple Myeloma (MM) — Dr Richardson (4:47) • Integration of Novel Therapies into the Management of Relapsed/Refractory (R/R) MM — Dr Lonial (30:01) • Chimeric Antigen Receptor (CAR) T-Cell Therapy for MM — Dr Raje (57:22) • Bispecific Antibodies in the Treatment of MM — Dr Krishnan (1:19:54) • Other Novel Agents and Strategies Under Investigation for MM — Dr Orlowski (1:37:56) CME information and select publications
2024-01-101h 55
PeerView Internal Medicine CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP, Krina Patel, MD, MSc - Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T and Antibody Options to Enhance Patient CareGo online to PeerView.com/MKV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CA...
2023-10-0743 minPeerView Oncology & Hematology CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP, Krina Patel, MD, MSc - Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T and Antibody Options to Enhance Patient CareGo online to PeerView.com/MKV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CA...
2023-10-0743 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP, Krina Patel, MD, MSc - Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T and Antibody Options to Enhance Patient CareGo online to PeerView.com/MKV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CA...
2023-10-0743 min
PeerView Internal Medicine CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP, Krina Patel, MD, MSc - Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T and Antibody Options to Enhance Patient CareGo online to PeerView.com/MKV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CA...
2023-10-0743 minPeerView Oncology & Hematology CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP, Krina Patel, MD, MSc - Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T and Antibody Options to Enhance Patient CareGo online to PeerView.com/MKV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CA...
2023-10-0743 minPeerView Clinical Pharmacology CME/CNE/CPE VideoSagar Lonial, MD, FACP, Krina Patel, MD, MSc - Setting New Expectations in Multiple Myeloma: Guidance on BCMA CAR-T and Antibody Options to Enhance Patient CareGo online to PeerView.com/MKV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are prepared to select the best care for your patients with multiple myeloma (MM) in this activity based on a symposium that was recorded at the Society of Hematologic Oncology’s 11th Annual Meeting. Join the MM experts as they workshop real-world issues of integrating anti-BCMA options into MM care while also providing solutions designed to speed up the integration of CAR-T and antibody platforms into patient management. Each interactive discussion will cover BCMA CA...
2023-10-0743 min
Research To Practice | Oncology VideosLymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma | Meet The Professors Live: Clinical Investigators Provide Perspectives on Actual Cases of Patients with Lymphoma, Chronic Lymphocytic Leukemia and Multiple MyelomaFeaturing perspectives from Dr John N Allan, Dr Shaji K Kumar, Dr Ann S LaCasce, Dr Sagar Lonial, Dr Loretta J Nastoupil and Dr Susan O'Brien, including the following topics: Multiple Myeloma Introduction (0:00) Initial treatment of newly diagnosed multiple myeloma (MM) (1:51) Sequencing of therapies for relapsed/refractory MM (21:34) Lymphoma Hodgkin lymphoma (52:12) Diffuse large B-cell lymphoma and follicular lymphoma (1:05:30) Mantle cell lymphoma (1:31:17) Chronic Lymphocytic Leukemia First-line treatment of chronic lymphocytic leukemia (1:41:23) Relapsed/refractory disease (2:14:23) Richter's transformation (2:22:50) CME information and select publications
2023-07-052h 30
The HemOnc PulseSagar Lonial, MD, FACP, on Why This MRD Approach Is ’Premature’ in MMBlood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, discusses how he approaches frontline therapy for multiple myeloma (MM), why he thinks certain approaches to minimal residual disease (MRD) in MM are “premature,” and the data that show why sustained MRD negativity is key, with host Chadi Nabhan, MD, MBA, FACP.
2023-05-0422 min
VJHemOnc PodcastiwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressedThe 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and researchers who discussed several topics. In this podcast series, you will hear the latest updates in the treatment of multiple myeloma and gain an insight into the sessions that took place at this year’s meeting.
In this podcast, Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone, New York City, NY, Pieter Sonneveld, MD, PhD, Erasmus University, Rotterdam, The Netherlands, and Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discuss the possibility of reaching a cu...
2023-05-0211 min
Research To Practice | Oncology VideosMultiple Myeloma | Addressing Current Questions and Controversies in the Management of Multiple Myeloma — What Clinicians Want to KnowFeaturing perspectives from Drs Jesús Berdeja, Rafael Fonseca, Sagar Lonial, Robert Orlowski and Noopur Raje, including the following topics: Front-Line Treatment of Multiple Myeloma (MM) Introduction (0:00) Case: A woman in her early 50s with newly diagnosed MM (NDMM) and 1q gain who presents with a pathologic fracture and receives daratumumab/RVd — Bhavana (Tina) Bhatnagar, DO (2:49) Cases: An otherwise healthy man in his late 80s with NDMM who is disinclined to undergo aggressive therapy and a transplant-ineligible woman in her late 70s with NDMM — Erik Rupard, MD and Hans Lee, MD (10:05) Dr Orlowski presentation (15:45) Integration of Novel Therapies into t...
2023-01-111h 58PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular TherapiesGo online to PeerView.com/FMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today...
2022-10-2954 minPeerView Oncology & Hematology CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - An "Off-the-Shelf" Approach for Myeloma Care: Visualizing the Present and Future of BCMA AntibodiesGo online to PeerView.com/EGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to integrate novel "off-the-shelf" BCMA-directed antibody-based therapies into the treatment of patients with multiple myeloma (MM)? This highly visual educational activity illustrates the mechanism of action for targeting BCMA in relapsed/refractory MM (RRMM) and brings to life the latest data on the use of antibody–drug conjugates (ADCs) and emerging bispecific T-cell engagers, along with team-based strategies for safely integrating these agents into treatment plans for older, triple-class refractory, and other challenging patients. Don't mi...
2022-10-2932 minPeerView Internal Medicine CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP - Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular TherapiesGo online to PeerView.com/FMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today...
2022-10-2954 minPeerView Internal Medicine CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP - An "Off-the-Shelf" Approach for Myeloma Care: Visualizing the Present and Future of BCMA AntibodiesGo online to PeerView.com/EGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to integrate novel "off-the-shelf" BCMA-directed antibody-based therapies into the treatment of patients with multiple myeloma (MM)? This highly visual educational activity illustrates the mechanism of action for targeting BCMA in relapsed/refractory MM (RRMM) and brings to life the latest data on the use of antibody–drug conjugates (ADCs) and emerging bispecific T-cell engagers, along with team-based strategies for safely integrating these agents into treatment plans for older, triple-class refractory, and other challenging patients. Don't mi...
2022-10-2932 minPeerView Internal Medicine CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular TherapiesGo online to PeerView.com/FMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today...
2022-10-2954 minPeerView Internal Medicine CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - An "Off-the-Shelf" Approach for Myeloma Care: Visualizing the Present and Future of BCMA AntibodiesGo online to PeerView.com/EGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to integrate novel "off-the-shelf" BCMA-directed antibody-based therapies into the treatment of patients with multiple myeloma (MM)? This highly visual educational activity illustrates the mechanism of action for targeting BCMA in relapsed/refractory MM (RRMM) and brings to life the latest data on the use of antibody–drug conjugates (ADCs) and emerging bispecific T-cell engagers, along with team-based strategies for safely integrating these agents into treatment plans for older, triple-class refractory, and other challenging patients. Don't mi...
2022-10-2932 minPeerView Oncology & Hematology CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP - An "Off-the-Shelf" Approach for Myeloma Care: Visualizing the Present and Future of BCMA AntibodiesGo online to PeerView.com/EGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to integrate novel "off-the-shelf" BCMA-directed antibody-based therapies into the treatment of patients with multiple myeloma (MM)? This highly visual educational activity illustrates the mechanism of action for targeting BCMA in relapsed/refractory MM (RRMM) and brings to life the latest data on the use of antibody–drug conjugates (ADCs) and emerging bispecific T-cell engagers, along with team-based strategies for safely integrating these agents into treatment plans for older, triple-class refractory, and other challenging patients. Don't mi...
2022-10-2932 minPeerView Oncology & Hematology CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP - Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular TherapiesGo online to PeerView.com/FMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today...
2022-10-2954 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular TherapiesGo online to PeerView.com/FMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today...
2022-10-2954 minPeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - An "Off-the-Shelf" Approach for Myeloma Care: Visualizing the Present and Future of BCMA AntibodiesGo online to PeerView.com/EGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to integrate novel "off-the-shelf" BCMA-directed antibody-based therapies into the treatment of patients with multiple myeloma (MM)? This highly visual educational activity illustrates the mechanism of action for targeting BCMA in relapsed/refractory MM (RRMM) and brings to life the latest data on the use of antibody–drug conjugates (ADCs) and emerging bispecific T-cell engagers, along with team-based strategies for safely integrating these agents into treatment plans for older, triple-class refractory, and other challenging patients. Don't mi...
2022-10-2932 minPeerView Clinical Pharmacology CME/CNE/CPE VideoSagar Lonial, MD, FACP - Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular TherapiesGo online to PeerView.com/FMJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This “MasterClass & Case Forum” program utilizes a linked foundational lecture and case-based approach to highlight recent advances with B-cell maturation antigen (BCMA)–targeted therapies and illustrate their effects on outcomes in relapsed/refractory multiple myeloma (RRMM). Each case-centered session includes an assessment of the relevant evidence supporting the use of BCMA-directed antibodies and CAR-T therapy. Expert-led, case-based instruction on patient assessment, therapy selection, dosing and scheduling, and management of unique treatment-related AEs is built on this foundation. Watch today...
2022-10-2954 minPeerView Clinical Pharmacology CME/CNE/CPE VideoSagar Lonial, MD, FACP - An "Off-the-Shelf" Approach for Myeloma Care: Visualizing the Present and Future of BCMA AntibodiesGo online to PeerView.com/EGA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to integrate novel "off-the-shelf" BCMA-directed antibody-based therapies into the treatment of patients with multiple myeloma (MM)? This highly visual educational activity illustrates the mechanism of action for targeting BCMA in relapsed/refractory MM (RRMM) and brings to life the latest data on the use of antibody–drug conjugates (ADCs) and emerging bispecific T-cell engagers, along with team-based strategies for safely integrating these agents into treatment plans for older, triple-class refractory, and other challenging patients. Don't mi...
2022-10-2932 min
Research To Practice | Oncology VideosMultiple Myeloma | Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 1Featuring perspectives from Dr Sagar Lonial, including the following topics: Journal Club with Sagar Lonial, MD — Part 1 (0:00) Case: A man in his late 50s with relapsed t(11;14) multiple myeloma (MM) 17 years after initial induction treatment and ASCT — Rajalaxmi McKenna, MD (16:45) Case: A man in his mid 70s with NDMM receives daratumumab/lenalidomide/dexamethasone in EAA181 clinical trial and develops ileus — Erik Rupard, MD (31:09) Case: A man in his early 80s with NDMM, a borderline performance status and multiple medical comorbidities, including DM, CHF and CKD — Ranju Gupta, MD (35:18) Case: A woman in her late 60s with biochemical progression of del(1...
2022-10-281h 02CME in Minutes: Education in Primary CareSagar Lonial, MD - Rebooting the Treatment of Relapsed/Refractory Multiple Myeloma: A New Look at Novel Cereblon-Targeted AgentsPlease visit answersincme.com/NMC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses rationale for—and clinical impact of—cereblon (CRBN) E3 ligase modulators (CELMoDs) in treating relapsed/refractory multiple myeloma (RRMM), including clinical considerations for their future use. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for investigating novel therapies to address unmet treatment needs for relapsed/refractory multiple myeloma; Review the biologic rationale for targeting cereblon with novel therapies for RRMM; Describe the clinical impact of emerging CRBN...
2022-10-0112 min
PeerView Immunology & Transplantation CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular TherapyGo online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in M...
2022-08-101h 04PeerView Internal Medicine CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular TherapyGo online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in M...
2022-08-101h 04
PeerView Immunology & Transplantation CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular TherapyGo online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in M...
2022-08-101h 04PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular TherapyGo online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in M...
2022-08-101h 04PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular TherapyGo online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in M...
2022-08-101h 04PeerView Internal Medicine CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular TherapyGo online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in M...
2022-08-101h 04PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular TherapyGo online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in M...
2022-08-101h 04PeerView Clinical Pharmacology CME/CNE/CPE VideoSagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular TherapyGo online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in M...
2022-08-101h 04PeerView Oncology & Hematology CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular TherapyGo online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in M...
2022-08-101h 04PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular TherapyGo online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, collaborative care. In this video activity, a hematologist-oncologist and an oncology nurse will highlight the importance of interprofessional collaboration when applying the new "ABCs" of patient management in M...
2022-08-101h 04
Cancer.Net Podcast2022 Research Round Up: Multiple Myeloma, Breast Cancer, and Cancer in Adults 60 and OverASCO: You’re listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests’ statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, acti...
2022-07-2831 min
MedEdTalks - OphthalmologyMultidisciplinary Strategies to Reduce the Burden of Ocular Toxicities in Myeloma With Drs. Sagar Lonial and Asim V. FarooqIn this podcast, expert clinicians will discuss best practices for reducing ocular toxicities in myeloma patients through the multidisciplinary team.
2022-01-3115 minMedEdTalks - OphthalmologyManaging Ocular Toxicities in Patients on Multiple Myeloma Therapy With Drs. Sagar Lonial and Asim V. FarooqIn this podcast, expert clinicians will discuss strategies to mitigate and manage ocular toxicities related to multiple myeloma therapy.
2022-01-3116 minMedEdTalks - OphthalmologyFrequency and Identification of Ocular Toxicities Associated With Myeloma Therapy With Drs. Sagar Lonial and Bennie JengIn this podcast, expert clinicians will discuss the frequency and identification of ocular toxicities of patients on myeloma therapy.
2022-01-3113 minMedEdTalks - OphthalmologyMechanisms Underlying Ocular Toxicities in Cancer Therapy With Drs. Bennie Jeng and Sagar LonialIn this podcast, expert clinicians will discuss the mechanisms behind ocular toxicities that have been associated with antibody drug conjugates used for cancer treatment.
2022-01-3114 minMultiple Myeloma HubShould 'cure' be the goal for multiple myeloma?During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma?This podcast captures the roundtable discussion with Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University (Paris, FR), María-Victoria Mateos, University Hospital of Salamanca (Salamanca, ES), and Sagar Lonial, Winship Cancer Institute of Emory University (Atlanta, US), and includes the concluding remarks of the Satellite Symposium as a whole. Hosted on Acast. See acast.com/privacy for more information.
2021-10-1428 minPeerView Oncology & Hematology CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma CareGo online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. This unique "Seminars and Tumor Board” video will provide a window into how an interprofessional team works together to select antibody-based treatment, address dose optimization, and manage adverse events to ult...
2021-10-141h 04PeerView Clinical Pharmacology CME/CNE/CPE VideoSagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma CareGo online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. This unique "Seminars and Tumor Board” video will provide a window into how an interprofessional team works together to select antibody-based treatment, address dose optimization, and manage adverse events to ult...
2021-10-141h 04PeerView Internal Medicine CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma CareGo online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. This unique "Seminars and Tumor Board” video will provide a window into how an interprofessional team works together to select antibody-based treatment, address dose optimization, and manage adverse events to ult...
2021-10-141h 04PeerView Internal Medicine CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma CareGo online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. This unique "Seminars and Tumor Board” video will provide a window into how an interprofessional team works together to select antibody-based treatment, address dose optimization, and manage adverse events to ult...
2021-10-141h 04PeerView Heart, Lung & Blood CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma CareGo online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. This unique "Seminars and Tumor Board” video will provide a window into how an interprofessional team works together to select antibody-based treatment, address dose optimization, and manage adverse events to ult...
2021-10-141h 04PeerView Oncology & Hematology CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma CareGo online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. This unique "Seminars and Tumor Board” video will provide a window into how an interprofessional team works together to select antibody-based treatment, address dose optimization, and manage adverse events to ult...
2021-10-141h 04PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastSagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma CareGo online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. This unique "Seminars and Tumor Board” video will provide a window into how an interprofessional team works together to select antibody-based treatment, address dose optimization, and manage adverse events to ult...
2021-10-141h 04PeerView Heart, Lung & Blood CME/CNE/CPE Video PodcastSagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma CareGo online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. This unique "Seminars and Tumor Board” video will provide a window into how an interprofessional team works together to select antibody-based treatment, address dose optimization, and manage adverse events to ult...
2021-10-141h 04Multiple Myeloma HubIs transplantation still relevant? If yes, in what context?During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US, answered: Is transplantation still relevant? If yes, in which context?In this podcast, Lonial describes results from the FORTE (NCT02203643) and IFM 2009 (NCT01191060) trials, which investigated the use of triplet combinations with and without transplant. He warns of the 'siren song' of early MRD negativity that may lead one to believe novel agents are just as good as...
2021-09-3013 min
The Our Stories PodcastOur Stories Ep.33 (Sagar Lonial)Sagar Lonial, MD, FACPChief Medical OfficerWinship Cancer Institute of Emory UniversityProfessor and Chair, Department of Hematology and Medical OncologyEmory University School of MedicineAnne and Bernard Gray Family Chair in CancerEmory University School of MedicineHematologistMultiple MyelomaBone Marrow and Stem Cell Transplant CenterPhase I Clinical Trials UnitResearch ProgramDiscovery and Developmental Therapeutics
2021-09-1623 min
Decera Clinical Education Oncology PodcastExpert Insights on Highlights From ASH 2020 on Multiple MyelomaIn this episode, Dr. Shaji Kumar from the Mayo Clinic and Dr. Sagar Lonial from Emory University discuss highlights of the key data from ASH 2020 on the treatment of patients with multiple myeloma. Topics include:Newly diagnosed multiple myelomaRelapsed/refractory multiple myelomaAnti-BCMA therapy: CAR T-cellsAnti-BCMA therapy: bispecific antibodiesAnti-BCMA therapy: antibody–drug conjugatesNovel targeted agents for relapsed/refractory multiple myelomaPresenters:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematological MalignanciesChair, Myeloma Amyloidosis Dysproteinemia GroupConsultant, Division of HematologyMayo ClinicRochester, MinnesotaSagar Lonial, MD
2021-03-1238 min
Healthcare UnfilteredEpisode 17: Debates and Controversies in Multiple MyelomaVincent Rajkumar, (@VincentRK), MD, hematologist at the Mayo Clinic (Rochester, MN), joins the show to guest host a debate between Sagar Lonial (@SagarLonialMD), MD, FACP, chief medical officer of Winship Cancer Institute of Emory University, and Rafael Fonseca, (@Rfonsi1), MD, interim director of Mayo Clinic Cancer Center. These multiple myeloma “gurus” dive into imaging, smoldering disease, endpoints, maintenance, minimal residual disease, and so much more.
2021-02-091h 12
MediCom Oncology Clinical Pearls PodcastsELOQUENT-2 updates represent the longest median FU of an immuno-oncology agent in MMDr. Sagar Lonial provides a brief update on the ELOQUENT-2 phase 3 trial and how it continues to demonstrate a benefit in terms of progression-free survival.
2017-07-1201 min